July 07, 2011 05:35 PM Eastern Daylight Time
InVivo Therapeutics Submits IDE Application to FDA for Spinal Cord Injury Clinical Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics (OTCBB: NVIV) today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.